This launch follows AstraZeneca’s receipt of Import and Market Permission from the DCGI on Sept 30, 2023
Contact Details : Email id : [email protected] | Phone No : +91 79681 99999 | Mobile No : +91 99780 60400
Links
Important Links : Fund Transfer – NEFT/RTGS | Relitrade IPO | Mandatory Information | Downloads | Contact Us | Careers | Life at Relitrade | Service Feedback | KYC Validation Link
Company : Pricing Details | Privacy Policy | Terms of Service | Refund and Cancellation | Disclaimer
Useful Links : SEBI | RBI | NSE INDIA | BSE INDIA | MCX INDIA | CDSL INDIA | NSDL | AMFI | SCORES 2.0 | SMART ODR | CDSL E-VOTING
Group Website : Relitrade IPO | Relitrade Mutual Funds | Easilywork | Policy Klub |
CIN : U67120GJ2012PTC116832 | NSE MEM NO : 14905 | BSE MEM NO : 6606 | MCX MEM NO : 46580 | CDSL :- IN-DP-CDSL-405-2019 | AMFI Reg.No: ARN-147999 | SEBI REG NO : INZ000184331
Trading and investments in Equities and Commodities are subject to market risk, there is no assurance or guarantee of the returns. Please read the Risk Disclosure Document and Do’s & Dont’s prescribed by the Exchanges carefully before investing.
Customer having any query/feedback/ clarification may for Securities Broking write to [email protected]
All Rights Reserved | © Copyright 2024 | Powered by BETANET
Reach us on WhatsApp